Researchers at the Weizmann Institute of Science have identified a biomarker that may one day enable a subgroup of lung cancer patients to benefit from relapse-free treatment. Non-smokers who develop lung cancer can be treated effectively with new drugs, but their...
New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy. Researchers at the Weizmann Institute of Science, in collaboration with physicians, have conducted a...